Therapeutic potential of 20(S)-ginsenoside Rg3 against streptozotocin-induced diabetic renal damage in rats

European Journal of Pharmacology

Volumn 591, Issue 1-3, 2008, Pages 266-272

  Kang, Ki Sung ^a   Yamabe, Noriko ^a   Kim, Hyun Young ^b   Park, Jeong Hill ^b   Yokozawa, Takako ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Seoul National University   (South Korea)

Author keywords

20(S) ginsenoside Rg3; Advanced glycation endproduct; N methyl D aspartate receptor; Oxidative stress; Streptozotocin induced diabetes

Indexed keywords

20(S) GINSENOSIDE RG3; 3 NITROTYROSINE; ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; CREATININE; CYCLOOXYGENASE 2; GINSENG EXTRACT; GLUCOSE; GLYCOSYLATED PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; STREPTOZOCIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DOSE RESPONSE; FLUID INTAKE; GINSENG; GLUCOSE BLOOD LEVEL; KIDNEY DYSFUNCTION; MALE; MEDICINAL PLANT; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; URINE VOLUME;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING; GINSENOSIDES; GLYCOSYLATION; MALE; OXIDATIVE STRESS; PANAX; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; STREPTOZOCIN; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 48849092302     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.06.077     Document Type: Article

References (49)

1. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res. Clin. Pract. 67 (2005) 3-21
2. Bankir L., Bardoux P., and Ahloulay M. Vasopressin and diabetes mellitus. Nephron 87 (2001) 8-18
3. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 40 (1991) 405-412
4. Blantz R.C., Deng A., Lortie M., Munger K., Vallon V., Gabbai F.B., and Thomson S.C. The complex role of nitric oxide in the regulation of glomerular ultrafiltration. Kidney Int. 61 (2002) 782-785
5. Chen H., Brahmbhatt S., Gupta A., and Sharma A.C. Duration of streptozotocin-induced diabetes differentially affects p38-mitogen-activated protein kinase (MAPK) phosphorylation in renal and vascular dysfunction. Cardiovasc. Diabetol. 4 (2005) 3
6. Cooper M.E. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 44 (2001) 1957-1972
7. Courderot-Masuyer C., Dalloz F., Maupoil V., and Rochette L. Antioxidant properties of aminoguanidine. Fundam. Clin. Pharmacol. 13 (1999) 535-540
8. Daulhac L., Mallet C., Courteix C., Etienne M., Duroux E., Privat A., Eschalier A., and Fialip J. Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-d-aspartate-dependent mechanisms. Mol. Pharmacol. 70 (2006) 1246-1254
9. de Arriba S.G., Krügel U., Regenthal R., Vissiennon Z., Verdaguer E., Lewerenz A., García-Jordá E., Pallas M., Camins A., Münch G., Nieber K., and Allgaier C. Carbonyl stress and NMDA receptor activation contribute to methylglyoxal neurotoxicity. Free Radic. Biol. Med. 40 (2006) 779-790
10. Deng A., Valdivielso J.M., Munger K.A., Blantz R.C., and Thomson S.C. Vasodilatory N-methyl-d-aspartate receptors are constitutively expressed in rat kidney. J. Am. Soc. Nephrol. 13 (2002) 1381-1384
11. Figarola J.L., Scott S., Loera S., Xi B., Synold T., Weiss L., and Rahbar S. Prevention of early renal disease, dyslipidaemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74, novel AGE inhibitors. Diabetes Metab. Res. Rev. 21 (2005) 533-544
12. Ic. FEBS Lett. 71 (1976) 356-360
13. Horie K., Miyata T., Maeda K., Miyata S., Sugiyama S., Sakai H., van Ypersole de Strihou C., Monnier V.M., Witztum J.L., and Kurokawa K. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J. Clin. Invest. 100 (1997) 2995-3004
14. Itzhaki R.F., and Gill D.M. A micro-biuret method for estimating proteins. Anal. Biochem. 9 (1964) 401-410
15. Kang K.S., Kim H.Y., Yamabe N., Nagai R., and Yokozawa T. Protective effect of sun ginseng against diabetic renal damage. Biol. Pharm. Bull. 29 (2006) 1678-1684
16. Kang K.S., Kim H.Y., Yamabe N., and Yokozawa T. Stereospecificity in hydroxyl radical scavenging activities of four ginsenosides produced by heat processing. Bioorg. Med. Chem. Lett. 16 (2006) 5028-5031
17. 2 by heat processing. Biol. Pharm. Bull. 30 (2007) 724-728
18. Kang K.S., Yokozawa T., Yamabe N., Kim H.Y., and Park J.H. ESR study on the structure and hydroxyl radical-scavenging activity relationships of ginsenosides isolated from Panax ginseng C. A. Meyer. Biol. Pharm. Bull. 30 (2007) 917-921
19. Kedziora-Kornatowska K., and Luciak M. Effect of aminoguanidine on lipid peroxidation and activities of antioxidant enzymes in the diabetic kidney. Biochem. Mol. Biol. Int. 46 (1998) 577-583
20. 3 on phorbol ester-induced cyclooxygenase-2 expression, NF-κB activation and tumor promotion. Mutat. Res. 523-524 (2003) 75-85
21. Kim H.Y., Kang K.S., Yamabe N., Nagai R., and Yokozawa T. Protective effect of heat-processed American ginseng against diabetic renal damage. J. Agric. Food Chem. 55 (2007) 8491-8497
22. 3 antagonizes NMDA receptors through a glycine modulatory site in rat cultured hippocampal neurons. Biochem. Biophys. Res. Commun. 323 (2004) 416-424
23. Leung J.C., Travis B.R., Verlander J.W., Sandhu S.K., Yang S., Zea A.H., Weiner I.D., and Silverstein D.M. Expression and developmental regulation of the NMDA receptor subunits in the kidney and cardiovascular system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283 (2002) R964-R971
24. Leung J.C., Marphis T., Craver R.D., and Silverstein D.M. Altered NMDA receptor expression in renal toxicity: protection with a receptor antagonist. Kidney Int. 66 (2004) 167-176
25. Levin A. Identification of patients and risk factors in chronic kidney disease-evaluating risk factors and therapeutic strategies. Nephrol. Dial. Transplant. 16 (2001) 57-60
26. Mihara M., and Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal. Biochem. 86 (1978) 271-278
27. ε-(carboxymethyl)lysine by the cleavage of Amadori product and generation of glucosone and glyoxal from glucose. Novel pathways for protein modification by peroxynitrite. Diabetes 51 (2002) 2833-2839
28. Naito C., and Yamanaka T. Lipid peroxides in atherosclerotic diseases. Nippon Ronen Igakkai Zasshi 15 (1978) 187-191
29. Nakayama H., Mitsuhashi T., Kuwajima S., Aoki S., Kuroda Y., Itoh T., and Nakagawa S. Immunochemical detection of advanced glycation end products in lens crystallins from streptozotocin-induced diabetic rat. Diabetes 42 (1993) 345-350
30. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., Yorek M.A., Beebe D., Oates P.J., Hammes H., Giardino I., and Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 404 (2000) 787-790
31. Notenboom S., Miller D.S., Smits P., Russel F.G.M., and Masereeuw R. Role of NO in endohelin-regulated drug transport in the renal proximal tubule. Am. J. Physiol. Renal Physiol. 282 (2002) F458-F464
32. Park J.H., Kim J.M., Han S.B., Kim N.Y., Surh Y.J., Lee S.K., Kim N.D., and Park M.K. A new processed ginseng with fortified activity. In: Huh H., Choi K.J., and Kim Y.C. (Eds). Advances in Ginseng Research (1998), Korean Society of Ginseng, Seoul 146-159
33. Price D.L., Rhett P.M., Thorpe S.R., and Baynes J.W. Chelating activity of advanced glycation end-products inhibitors. J. Biol. Chem. 276 (2001) 48967-48972
34. Rangan G.K., Wang Y., Tay Y.C., and Harris D.C. Inhibition of nuclear factor-κB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int. 56 (1999) 118-134
35. Schrijvers B.F., Vriese A.S.D., and Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr. Rev. 25 (2004) 971-1010
36. Soulis-Liparota T., Cooper M., Papazoglou D., Clarke B., and Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40 (1991) 1328-1334
37. Surh Y.J., Chun K.S., Cha H.H., Han S.S., Keum Y.S., Park K.K., and Lee S.S. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-κB activation. Mutat. Res. 480-481 (2001) 243-268
38. Surh Y.J., Na H.K., Lee J.Y., and Keum Y.S. Molecular mechanisms underlying anti-tumor promoting activities of heat-processed Panax ginseng C.A. Meyer. J. Korean Med. Sci. 16 (2001) S38-S41
39. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1993) 977-986
40. Turk H.M., Sevinc A., Camci C., Cigli A., Buyukberber S., Savli H., and Bayraktar N. Plasma lipid peroxidation products and antioxidant enzyme activities in patients with type 2 diabetes mellitus. Acta Diabetol. 39 (2002) 117-122
41. Tuttle K.R., Johnson E.C., Cooney S.K., Anderberg R.J., Johnson E.K., Clifton G.D., and Meek R.L. Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C. Kidney Int. 67 (2005) 953-968
42. Virág L., Szabó É., Gergely P., and Szabó S. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol. Lett. 140-141 (2003) 113-124
43. Vlassara H., Striker L.J., Teichberg S., Fuh H., Li Y.M., and Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. USA 91 (1994) 11704-11708
44. Warne J.P., Horneman H.F., Wick E.C., Bhargava A., Pecoraro N.C., Ginsberg A.B., Akana S.F., and Dallman M.F. Comparison of superior mesenteric versus jugular venous infusions of insulin in streptozotocin-diabetic rats on the choice of caloric intake, body weight, and fat stores. Endocrinology 147 (2006) 5443-5451
45. Wendt T., Tanji N., Guo J., Hudson B.I., Bierhaus A., Ramasamy R., Arnold B., Nawroth P.P., Yan S.F., D, Agati V., and Schmidt A.M. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J. Am. Soc. Nephrol. 14 (2003) 1383-1395
46. Williams M.E. New therapies for advanced glycation end product nephrotoxicity: current challenges. Am. J. Kidney Dis. 41 (2003) S42-S47
47. Yamabe N., Kang K.S., Goto E., Tanaka T., and Yokozawa T. Beneficial effect of Corni Fructus, a constituent of Hachimi-jio-gan, on advanced glycation end-product-mediated renal injury in streptozotocin-treated diabetic rats. Biol. Pharm. Bull. 30 (2007) 520-526
48. Y an S.D., Schmidt A.M., Anderson G.M., Zhang J., Brett J., Zou Y.S., Pinsky D., and Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 269 (1994) 9889-9897
49. Yokozawa T., Yamabe N., Cho E.J., Nakagawa T., and Oowada S. A study on the effects to diabetic nephropathy of Hachimi-jio-gan in rats. Nephron Exp. Nephrol. 97 (2004) 38-48